Hangzhou Tigermed Consulting Co., Ltd. (3347.HK)
3347.HK Stock Price Chart
Explore Hangzhou Tigermed Consulting Co., Ltd. interactive price chart. Choose custom timeframes to analyze 3347.HK price movements and trends.
3347.HK Company Profile
Discover essential business fundamentals and corporate details for Hangzhou Tigermed Consulting Co., Ltd. (3347.HK) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
IPO Date
7 Aug 2020
Employees
10.19K
Website
https://www.tigermed.netCEO
Xiaoping Ye D.Phil, EMBA,
Description
Hangzhou Tigermed Consulting Co., Ltd. provides contract research organization services in the People's Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers regulatory submission and approval, medical translation, and good manufacturing practice (GMP) consulting services; and clinical services in the areas of medical science, early clinical and late phase development, medical monitoring, project management, patient recruitment, and quality management system. It also provides biometrics services comprising data management, biostatistics, and statistical programming; and integrated technology services, such as site management, pharmacovigilance, third party audit and training, medical imaging, clinical trial system solution, central laboratory, pre-clinical, and research hospital. Further, the company offers medical device/ in vitro diagnostics (IVD) services comprising medical device testing, regulatory submission, clinical evaluation and trials, GMP certificate, EU MDR and IVDR preparation, and value-added services; and post-marketing study, real world evidence, and vaccine clinical trial services. Hangzhou Tigermed Consulting Co., Ltd. was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.
3347.HK Financial Timeline
Browse a chronological timeline of Hangzhou Tigermed Consulting Co., Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 28 Apr 2026
Upcoming earnings on 27 Mar 2026
Upcoming earnings on 29 Oct 2025
Earnings released on 28 Aug 2025
EPS came in at $0.27 falling short of the estimated $0.38 by -28.48%, while revenue for the quarter reached $1.84B , beating expectations by +3.02%.
Dividend declared on 12 Jun 2025
A dividend of $0.32 per share was announced, adjusted to $0.32. The dividend was paid on 11 Jul 2025.
Earnings released on 28 Apr 2025
EPS came in at $0.20 falling short of the estimated $0.39 by -48.55%, while revenue for the quarter reached $1.67B , missing expectations by -10.00%.
Earnings released on 26 Mar 2025
EPS came in at -$0.50 falling short of the estimated $0.66 by -176.26%, while revenue for the quarter reached $1.63B , missing expectations by -3.45%.
Earnings released on 29 Oct 2024
EPS came in at $0.37 falling short of the estimated $0.59 by -37.29%, while revenue for the quarter reached $1.89B , missing expectations by -15.55%.
Earnings released on 28 Aug 2024
EPS came in at $0.33 surpassing the estimated $0.32 by +3.13%, while revenue for the quarter reached $1.82B , missing expectations by -18.61%.
Dividend declared on 7 Jun 2024
A dividend of $0.62 per share was announced, adjusted to $0.62. The dividend was paid on 18 Jul 2024.
Earnings released on 25 Apr 2024
EPS came in at $0.29 falling short of the estimated $0.57 by -49.02%, while revenue for the quarter reached $1.80B , missing expectations by -1.58%.
Earnings released on 28 Mar 2024
EPS came in at $0.17 falling short of the estimated $0.52 by -67.31%, while revenue for the quarter reached $1.92B , missing expectations by -6.12%.
Earnings released on 30 Sept 2023
EPS came in at $0.60 falling short of the estimated $0.77 by -21.28%, while revenue for the quarter reached $2.08B , missing expectations by -2.11%.
Earnings released on 30 Jun 2023
EPS came in at $1.03 surpassing the estimated $0.55 by +88.30%, while revenue for the quarter reached $2.06B , missing expectations by -3.03%.
Dividend declared on 25 May 2023
A dividend of $0.62 per share was announced, adjusted to $0.62. The dividend was paid on 7 Jul 2023.
Earnings released on 31 Mar 2023
EPS came in at $0.75 falling short of the estimated $0.80 by -6.34%, while revenue for the quarter reached $2.06B , missing expectations by -2.09%.
Earnings released on 29 Mar 2023
EPS came in at $0.46 falling short of the estimated $0.99 by -53.54%, while revenue for the quarter reached $1.86B , beating expectations by +11.08%.
Earnings released on 30 Sept 2022
EPS came in at $0.53 falling short of the estimated $0.74 by -29.44%, while revenue for the quarter reached $1.99B , beating expectations by +6.64%.
Earnings released on 25 Aug 2022
EPS came in at $0.78 surpassing the estimated $0.74 by +5.41%, while revenue for the quarter reached $2.08B , beating expectations by +36.72%.
Dividend declared on 24 May 2022
A dividend of $0.58 per share was announced, adjusted to $0.58. The dividend was paid on 20 Jun 2022.
Earnings released on 26 Apr 2022
EPS came in at $0.60 falling short of the estimated $0.76 by -20.84%, while revenue for the quarter reached $2.24B , beating expectations by +28.62%.
Earnings released on 11 Mar 2022
EPS came in at $1.27 surpassing the estimated $0.51 by +149.02%, while revenue for the quarter reached $2.23B , beating expectations by +20.40%.
Earnings released on 22 Oct 2021
EPS came in at $0.72 , while revenue for the quarter reached $1.61B .
Earnings released on 26 Aug 2021
EPS came in at $0.92 , while revenue for the quarter reached $1.39B .
Dividend declared on 25 May 2021
A dividend of $0.36 per share was announced, adjusted to $0.36. The dividend was paid on 21 Jun 2021.
Earnings released on 29 Apr 2021
EPS came in at $0.52 , while revenue for the quarter reached $1.07B .
Earnings released on 30 Mar 2021
EPS came in at $0.45 surpassing the estimated $0.38 by +18.42%, while revenue for the quarter reached $1.06B .
Earnings released on 30 Oct 2020
EPS came in at $0.39 falling short of the estimated $0.42 by -7.14%, while revenue for the quarter reached $967.45M .
3347.HK Stock Performance
Access detailed 3347.HK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.